S&E Bio

(주)에스엔이바이오

Seoul, South Korea · Founded 2019

Headquarters
Seoul
Employees
1–10
Founded
2019
Business Model
B2B
Website
snebio.com
Last Round
Series ADec 2022
Rounds
1

About

S&E bio is a South Korean biopharmaceutical company founded in 2019 by Professor Oh Young Bang of Samsung Medical Center, focused on developing cell-free stem cell therapeutics using mesenchymal stem cell-derived extracellular vesicles (exosomes). The company's lead candidate, SNE-101, received Korea's first MFDS approval in 2025 to begin a Phase 1b clinical trial for exosome-based stroke therapy. S&E bio uses a proprietary 3D culture system to optimize exosome production, with patents granted across Korea, the United States, Europe, and Japan covering its manufacturing methods and therapeutic compositions.

Summary

S&E Bio is a Biotech company based in Seoul, South Korea, founded in 2019. Its most recent funding was a Series A round in Dec 2022. Investors include KB Investment, Korea Investment Partners and Company K Partners.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries ADec 2022

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

S&E Bio on Indexed.vc
<a href="https://indexed.vc/companies/s-e-bio"><img src="https://indexed.vc/api/badge/company/s-e-bio" alt="S&E Bio on Indexed.vc" width="260" height="76" /></a>